Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.60 |
| ▸ | RAB9A | P51151 | 12/20 | 0.60 |
| ▸ | PKM | P14618 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22183247 | 0.83 | NPC1 (0.74) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL17488078 | 0.79 | NPC1 (0.68) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL9893073 | 0.78 | LMNA (0.63) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL28376644 | 0.76 | NPC1 (1.00) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL30334992 | 0.76 | NPC1 (1.00) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL26606534 | 0.76 | RAB9A (0.51) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL17488032 | 0.75 | RAB9A (0.67) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL10318990 | 0.75 | CYP3A4 (0.63) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL9892357 | 0.75 | MTOR (0.50) | NPC1RAB9APKMSMN1; SMN2KDM4E | |
| SCHEMBL9891928 | 0.75 | MTOR (0.50) | NPC1RAB9APKMSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | NPC1 1078/4885RAB9A 3169/4885PKM 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.